Details:
Bimervax is a recombinant protein vaccine whose active substance is SARS-CoV-2 virus recombinant spike (S) protein receptor binding domain (RBD) fusion heterodimer – B.1.351-B.1.1.7 strains, it provides immune response at humoral and cellular level, against the COVID-19.
Lead Product(s): Recombinant Protein Covid-19 Vaccine
Therapeutic Area: Infections and Infectious Diseases Product Name: Bimervax
Highest Development Status: Approved Product Type: Vaccine
Partner/Sponsor/Collaborator: Veristat
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 25, 2023
Details:
Bimervax is a recombinant protein vaccine whose active substance is SARS-CoV-2 virus recombinant spike (S) protein receptor binding domain (RBD) fusion heterodimer – B.1.351-B.1.1.7 strains, it provides immune response at humoral and cellular level, against the COVID-19.
Lead Product(s): Recombinant Protein Covid-19 Vaccine
Therapeutic Area: Infections and Infectious Diseases Product Name: Bimervax
Highest Development Status: Approved Product Type: Vaccine
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 30, 2023
Details:
This new agreement, which has a term of ten years, includes a series of investments expected to allow the manufacturing capacity of products including Spikevax, to increase across ROVI's facilities in Madrid, Spain.
Lead Product(s): Elasomeran
Therapeutic Area: Infections and Infectious Diseases Product Name: Spikevax
Highest Development Status: Approved Product Type: Vaccine
Partner/Sponsor/Collaborator: Moderna Therapeutics
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Expanded Collaboration February 16, 2022
Details:
This partnership will expand the reach of SOLOSEC®, allowing more Healthcare Providers to be aware of the benefits of SOLOSEC®, and increase access for adult women suffering with bacterial vaginosis and adults with trichomoniasis.
Lead Product(s): Secnidazole
Therapeutic Area: Infections and Infectious Diseases Product Name: Solosec
Highest Development Status: Approved Product Type: Small molecule
Partner/Sponsor/Collaborator: Lupin Ltd
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement January 27, 2022